Abstract
Human respiratory syncytial virus (RSV) is a cause of lower respiratory tract infection in infants, young children, and older adults. There is no licensed vaccine and prophylactic treatment options are limited. The RSV fusion (F) glycoprotein is a target of host immunity and thus a focus for vaccine development. F-trimers are metastable and undergo significant rearrangements from the prefusion to a stable postfusion structure with neutralizing epitopes on intermediate structures. We hypothesize that vaccine strategies that recapitulate the breathable F quaternary structure, and provide accessibility of B-cells to epitopes on intermediate conformations, may collectively contribute to protective immunity, while rigid prefusion F structures restrict access to key protective epitopes. To test this hypothesis, we used the near full-length prefusogenic F as a backbone to construct three prefusion F variants with substitutions in the hydrophobic head cavity: (1) disulfide bond mutant (DS), (2) space filling hydrophobic amino acid substitutions (Cav1), and (3) DS, Cav1 double mutant (DS-Cav1). In this study, we compared the immunogenicity of prefusogenic F to prefusion F variants in two animal models. Native prefusogenic F was significantly more immunogenic, producing high titer antibodies to prefusogenic, prefusion, and postfusion F structures, while animals immunized with DS or DS-Cav1 produced antibodies to prefusion F. Importantly, prefusogenic F elicited antibodies that target neutralizing epitopes including prefusion-specific site zero (Ø) and V and conformation-independent neutralizing sites II and IV. Immunization with DS or DS-Cav1 elicited antibodies primarily to prefusion-specific sites Ø and V with little or no antibodies to other key neutralizing sites. Animals immunized with prefusogenic F also had significantly higher levels of antibodies that cross-neutralized RSV A and B subtypes, while immunization with DS or DS-Cav1 produced antibodies primarily to the A subtype. We conclude that breathable trimeric vaccines that closely mimic the native F-structure, and incorporate strategies for B-cell accessibility to protective epitopes, are important considerations for vaccine design. F structures locked in a single conformation restrict access to neutralizing epitopes that may collectively contribute to destabilizing F-trimers important for broad protection. These results also have implications for vaccine strategies targeting other type 1 integral membrane proteins.
Highlights
Human respiratory syncytial virus (RSV) is a cause of lower respiratory infection (LRTI) in young children and older adult populations
We have described a prefusogenic RSV F (BV1184) vaccine candidate constructed from the near full-length RSV/A2 F-glycoprotein that form nanoparticles consisting of 3–5 F-trimers [30,31]
Using the prefusogenic F as a backbone, prefusion constructs were produced by introducing mutations within the hydrophobic cavity to stabilized the prefusion F structure as described by McLellan et al [22,23]
Summary
Human respiratory syncytial virus (RSV) is a cause of lower respiratory infection (LRTI) in young children and older adult populations. The disease burden is high in developing countries with over 3 million hospitalizations and 50,000–70,000 deaths in young children in 2015 [1]. Children under 5 years of age are the most susceptible and account for 45% of RSV-related deaths, with the vast majority (>90%) in developing countries [1]. The RSV disease burden is substantial in older adults with over 1 million infections, 300,000 hospitalizations, and over 10,000 in-hospital deaths worldwide in 2015 [2]. RSV is the cause of significant worldwide disease burden, there are no licensed vaccines and palivizumab (Synagis® ) is the only licensed prophylaxis for prevention of RSV in high-risk newborns. Unlike influenza where antibodies to hemaggulinin is a correlate for protective immunity, there is no established correlate of protective for RSV [3,4,5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.